AstraZeneca plc (NASDAQ: AZN) is rumored to be eyeing take over of Mereo BioPharma Group plc (NASDAQ: MREO), according to a report in The Times.
The Times’ report says that “Mereo would accept $5, equating to $500 million including American depositary receipts or ADRs. Evercore and Citigroup are said to be involved as advisers.”
Mereo’s lead drug, a TIGIT called etigilimab, is putting them in a race that disappointed after Roche …

Full story available on Benzinga.com

Read More